UPDATE: Bank of America Resumes Coverage on BioCryst Pharmaceuticals with Neutral Rating, $2 PT
Posted on February 04, 2013 at 09:05 AM EST
In a report published Monday, Bank of America resumed coverage on BioCryst Pharmaceuticals (NASDAQ: BCRX ) with a Neutral rating and $2.00 price target. Bank of America noted, “We are resuming coverage of BCRX with a Neutral rating and PO of $2, following the failed merger attempt with Presidio, the